Two phase 3 trials, KESTREL and KITE, identified brolucizumab as a viable diabetic macular edema treatment option, according to a study published in the American Journal of Ophthalmology.
“Brolucizumab 6 mg showed robust visual gains and anatomical improvements with an overall favorable benefit/risk profile in patients with DME,” David M. BrownMD, of Retina Consultants of Texas in Houston, and colleagues wrote.
Both studies were double-masked, multicenter trials that included adults with central-involved DME, HbA1c of 10% or less, best corrected visual acuity scores between